Lipodystrophy Is Common Among Ethiopian Patients on Highly Active Antiretroviral Therapy but Is Not Associated With Quality of Life or Medication Adherence
Restricted accessResearch articleFirst published online November, 2013
Lipodystrophy Is Common Among Ethiopian Patients on Highly Active Antiretroviral Therapy but Is Not Associated With Quality of Life or Medication Adherence
Clinical experience suggests that lipodystrophy (LD) can have a profound impact on quality of life (QOL) and medication adherence (MA). Thus, a hospital-based, cross-sectional study was conducted to determine the prevalence of LD and its association with QOL and MA. A total of 405 participants were included in the study. The majority of participants were female (64.5%), with a mean age of 35.69 years (SD = 9.63 years). The prevalence of LD was 30.9%. Multiple logistic regression analysis showed that type of regimen initially used is an independent predictor of severity of LD (adjusted odds ratio, 44.16; 95% confidence interval, 10.56-184.59; P = .001). Quality of life was assessed with the World Health Organization Quality of Life short form instrument (WHOQOL-BREF), and medication adherence was assessed by self-report. The mean WHOQOL-BREF score of the participants was 53.48; the highest mean value was in the domain of physical health (68.56) and the lowest was in the social relationships domain (47.09). The majority of the patients scored lower (ie, in the lowest 5 deciles) in the domains of psychological health, social relationships, and environment compared with physical health. No differences in the WHOQOL-BREF measurements were observed, except in the environment domain, between patients with moderate LD and severe LD (P = .02). The LD severity was not associated with self-reported MA (P = .42). With the exception of the psychological health domain (P = .044), participants’ WHOQOL-BREF scores were not significantly associated with MA. Lipodystrophy was not associated with QOL or MA. The prevalence of LD in the present study was within the range of previous reports; however, the mean WHOQOL-BREF score of Ethiopian patients in this study is lower compared with reports from developed countries.
CarrASamarasKBurtonS. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51–F58.
GoujardCBoufassaFDeveaaC. Incidence of clinical lipodystrophy in HIV-1 infected patients treated during primary infection. AIDS. 2001;15:282–284.
8.
van der ValkMCasulaMWeverlingGJ. Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allocated to zidovudine- or stavudine-based therapy. Antivir Ther. 2004;9:385–393.
9.
DomingoPCabezaMCPruvostA. Relationship between HIV/highly active antiretroviral therapy (HAART)–associated lipodystrophy syndrome and stavudine-triphosphate intracellular levels in patients with stavudine-based antiretroviral regimens. Clin Infect Dis. 2010;50:1033–1040.
10.
GervasoniCRidolfoALTrifiròG. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS. 1999;13:465–471.
11.
CarrASamarasKThorisdottirAKaufmannGRChisholmDJCooperDA.Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353:2093–2099.
12.
SchwenkABreuerJPKremerG. Risk factors for the HIV-associated lipodystrophy syndrome in a cross-sectional single-centre study. Eur J Med Res. 2000;5(10):443–448.
13.
PuttawongSPrasithsirikulWVadcharavivadS.Prevalence of lipodystrophy in Thai-HIV infected patients. J Med Assoc Thai. 2004;87(6):605–611.
VanGriensvenJDe NaeyerLMushiT. High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda. Trans R Soc Trop Med Hygiene. 2007;101(8):793–798.
18.
WomackJ.HIV-related lipodystrophy in Africa and Asia. AIDS Reader. 2009;19:131–139, 148–152.
19.
van der ValkMGisolfEHReissP. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS. 2001;15:847–855.
20.
GrunfeldCKotlerDPArnettDK. Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors. Circulation. 2008;118(2):e20–e28.
21.
MutimuraEStewartACrowtherNJ.Assessment of quality of life in HAART-treated HIV-positive subjects with body fat redistribution in Rwanda. AIDS Res Ther. 2007;4:19.
22.
CollinsEWagnerCWalmsleyS.Psychosocial impact of the lipodystrophy syndrome in HIV infection. AIDS Reader. 2000;10:546–550.
23.
The EuroQol Group. EuroQola new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208.
24.
SilvaCGAlchieriJC. Esthetic self-perception of HIV/AIDS patients under antiretroviral therapy suffering from lipodystrophic syndrome and its influence on the quality of life in a city of the Brazilian northeast. J Public Health Epidemiol. 2011;3(11):529–535.
25.
NoerholmVGroenvoldMWattTBjornerJBRasmussenNABechP.Quality of life in the Danish general population—normative data and validity of WHOQOLBREF using Rasch and item response theory models. Qual Life Res. 2004;13:531–540.
26.
BlanchJRousaudAMartýnezE. Impact of lipodystrophy on the quality of life of HIV-1–infected patients. J Acquir Immune Defic Syndr. 2002;31:404–407.
27.
BurgoyneRCollinsEWagnerC. The relationship between lipodystrophy-associated body changes and measures of quality of life and mental health for HIV-positive adults. Qual Life Res. 2005;14:981–990.
28.
GuaraldiGMurriROrlandoG. Severity of lipodystrophy is associated with decreased health-related quality of life. AIDS Patient Care STDS. 2008;22(7):577–585.
29.
DuranSASavesMSpireB. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS. 2001;15:2441–2444.
30.
AmmassariAAntinoriACozzi-LepriA. Relationship between HAART adherence and adipose tissue alterations. J Acquir Immune Defic Syndr. 2002;31:S140–S144.
31.
TienPCBarronYJustmanJE. Antiretroviral therapies associated with lipoatrophy in HIV-infected women. AIDS Patient Care STDS. 2007;21:297–305.
32.
CorlessIBKirkseyKMKemppainenJ. Lipodystrophy-associated symptoms and medication adherence in HIV/AIDS. AIDS Patient Care STDS. 2005;19(9):577–586.
33.
MannheimerSBMattsJTelzakE. Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence. AIDS Care. 2005;17(1):10–22.
34.
OetteMJuretzkoPKroidlA. Lipodystrophy syndrome and self-assessment of well-being and physical appearance in HIV-positive patients. AIDS Patient Care STDS. 2002;16:413–417.
35.
ReynoldsNRNeidigJLWuAW. Balancing disfigurement and fear of disease progression: patient perceptions of HIV body fat redistribution. AIDS Care. 2006;18:663–673.
36.
World Health Organization Programme on Mental Health. WHOQOL-BREF: Introduction, Administration, Scoring and Generic Version of the Assessment. Geneva, Switzerland: World Health Organization; 1996.
37.
MartinezEMocroftAGarcía-ViejoMA. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet. 2001;357(9256):592–598.
38.
CarterVMHoyJFBaileyMColmanPGNyulasiIMijchAM.The prevalence of lipodystrophy in an ambulant HIV-infected population: it all depends on the definition. HIV Med. 2001;2:174–180.
39.
MallalSJohnMMooreC. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in HIV infection. AIDS. 2000;14:1309–1316.
40.
DomingoPCabezaMCPruvostA. Relationship between HIV/highly active antiretroviral therapy (HAART)–associated lipodystrophy syndrome and stavudine-triphosphate intracellular levels in patients with stavudine-based antiretroviral regimens. Clin Infect Dis. 2010;50:1033–1040.
41.
ChêneGAngeliniECotteL. Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus–infected patients. Clin Infect Dis. 2002;34(5):649–657.
42.
NoerholmVGroenvoldMWattTBjornerJBRasmussenNABechP.Quality of life in the Danish general population—normative data and validity of WHOQOLBREF using Rasch and item response theory models. Qual Life Res. 2004;13:531–540.
43.
BlanchJRousaudAMartýnezE. Impact of lipodystrophy on the quality of life of HIV-1–infected patients. J Acquir Immune Defic Syndr. 2002;31:404–407.
44.
SchrootenWColebundersRYouleM. Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment. AIDS. 2001;15:1019–1023.
45.
DukersNStolteIGAlbrechtN. The impact of experiencing lipodystrophy on the sexual behavior and well-being among HIV infected homosexual men. AIDS. 2001;15:812–813.
46.
GuaraldiGLuziKMurriR. Sexual dysfunction in HIV-infected men: role of antiretroviral therapy, hypogonadism and lipodystrophy. Antiviral Ther. 2007;12:1059–1065.
47.
DuranSASavesMSpireB. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS. 2001;15:2441–2444.
